BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7202490)

  • 1. Human platelet 5HT receptors: characterisation and functional association.
    Peters JR; Grahame-Smith DG
    Eur J Pharmacol; 1980 Dec; 68(3):243-56. PubMed ID: 7202490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of the binding of [3H]-GR32191 to the thromboxane (TP-) receptor of human platelets.
    Armstrong RA; Humphrey PP; Lumley P
    Br J Pharmacol; 1993 Oct; 110(2):539-47. PubMed ID: 8242228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-affinity binding of [3H]6-nitroquipazine to 5-hydroxytryptamine transporter in human platelets.
    Hashimoto K; Goromaru T
    Eur J Pharmacol; 1990 Oct; 187(3):295-302. PubMed ID: 2073917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha 2-adrenoreceptors on human platelets: selective labelling by [3H]clonidine and [3H]yohimbine and competitive inhibition by antidepressant drugs.
    García-Sevilla JA; Hollingsworth PJ; Smnith CB
    Eur J Pharmacol; 1981 Sep; 74(4):329-41. PubMed ID: 6271559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets.
    Bevan J; Heptinstall S
    Thromb Res; 1983 Jun; 30(5):415-23. PubMed ID: 6612677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanism of action of various psychotropic agents on serotonin receptors and the transmembrane signal control].
    Mikuni M
    Hokkaido Igaku Zasshi; 1987 May; 62(3):417-29. PubMed ID: 3610034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of chlorprothixene isomers on platelet 5-hydroxytryptamine receptors: evidence for different 5-hydroxytryptamine conformations at uptake and stimulatory sites.
    Drummond AH; Whigham KA; Prentice CR
    Eur J Pharmacol; 1976 Jun; 37(2):385-8. PubMed ID: 954816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urapidil inhibits 5-hydroxytryptamine induced platelet aggregation and 14C-5-hydroxytryptamine uptake in platelets.
    Storck J; Kirsten R
    Curr Med Res Opin; 1990; 12(2):86-92. PubMed ID: 2390867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The binding characteristics of [3H]-dihydroergocryptine on intact human platelets.
    Elliott JM; Grahame-Smith DG
    Br J Pharmacol; 1982 May; 76(1):121-30. PubMed ID: 6805543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.
    Armstrong RA; Lawrence RA; Jones RL; Wilson NH; Collier A
    Br J Pharmacol; 1989 Jul; 97(3):657-68. PubMed ID: 2474350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of [3H]SR 27417, a novel platelet-activating factor (PAF) receptor antagonist, to rabbit and human platelets and polymorphonuclear leukocytes.
    Herbert JM; Laplace MC; Maffrand JP
    Biochem Pharmacol; 1993 Jan; 45(1):51-8. PubMed ID: 8381007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PAF binding sites. Characterization by [3H]52770 RP, a pyrrolo[1,2-c]thiazole derivative, in rabbit platelets.
    Robaut C; Durand G; James C; Lave D; Sedivy P; Floch A; Mondot S; Pacot D; Cavero I; Le Fur G
    Biochem Pharmacol; 1987 Oct; 36(19):3221-9. PubMed ID: 2822048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of 14C-5-hydroxytryptamine by human and rat platelets and its pharmacological inhibition. A comparative kinetic analysis.
    Wielosz M; Salmona M; de Gaetano G; Garattini S
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Dec; 296(1):59-65. PubMed ID: 1012348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet.
    Terashita Z; Imura Y; Nishikawa K
    Biochem Pharmacol; 1985 May; 34(9):1491-5. PubMed ID: 2986648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of [3H]lysergic acid diethylamide binding to a 5-hydroxytryptamine receptor on human platelet membranes.
    Geaney DP; Schächter M; Elliot JM; Grahame-Smith DG
    Eur J Pharmacol; 1984 Jan; 97(1-2):87-93. PubMed ID: 6698111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.
    Korth R; Hirafuji M; Keraly CL; Delautier D; Bidault J; Benveniste J
    Br J Pharmacol; 1989 Oct; 98(2):653-61. PubMed ID: 2555017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for serotonin (5HT) binding sites on murine lymphocytes.
    Bonnet M; Lespinats G; Burtin C
    Int J Immunopharmacol; 1987; 9(5):551-8. PubMed ID: 3623772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 5-hydroxytryptamine system of blood platelets: physiology and pathophysiology.
    Pletscher A
    Int J Cardiol; 1987 Feb; 14(2):177-88. PubMed ID: 3818134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of alpha 2-adrenoceptors in rat cortex but not human platelets can be defined by 8-OH-DPAT, RU 24969 and methysergide.
    Brown CM; MacKinnon AC; McGrath JC; Spedding M; Kilpatrick AT
    Br J Pharmacol; 1990 Mar; 99(3):481-6. PubMed ID: 1970497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of serotonin binding sites on human platelets.
    McBride PA; Mann JJ; McEwen B; Biegon A
    Life Sci; 1983 Nov; 33(20):2033-41. PubMed ID: 6645789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.